Lazard

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Retrieved on: 
Friday, March 1, 2024

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Key Points: 
  • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
  • In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets.

Saba Launches Campaign to Improve the Boards of 10 Poorly Governed and Underperforming Closed-End Funds Managed by BlackRock

Retrieved on: 
Wednesday, March 6, 2024

Last year, a leading independent proxy advisory firm chastised BlackRock for its ‘ abusive’ governance.

Key Points: 
  • Last year, a leading independent proxy advisory firm chastised BlackRock for its ‘ abusive’ governance.
  • Saba also won a lawsuit against BlackRock that should have ended its illegal efforts to deprive shareholders of their right to vote all of their shares.
  • BlackRock acts as if federal law does not apply to its CEFs by blatantly ignoring the Investment Company Act.
  • Under the Entrenchment Bylaw, any share not voted in a contested election is counted as a vote for BlackRock.

Milestone Appoints Barbara Burger to Board

Retrieved on: 
Tuesday, February 27, 2024

Milestone Environmental Services, LLC (“Milestone” or the “Company”), a leading environmental services and carbon management company and the largest energy waste sequestration company in the United States, today announced that Barbara J. Burger, PhD, has been appointed to the Company’s Board of Managers, effective February 17, 2024.

Key Points: 
  • Milestone Environmental Services, LLC (“Milestone” or the “Company”), a leading environmental services and carbon management company and the largest energy waste sequestration company in the United States, today announced that Barbara J. Burger, PhD, has been appointed to the Company’s Board of Managers, effective February 17, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240227696477/en/
    Barbara J. Burger, PhD, who joined Milestone Environmental Services' Board of Managers on February 17, 2024, is a former Chevron executive with 36 years of industry and energy transition expertise.
  • (Photo: Business Wire)
    “I am very pleased to welcome Dr. Barbara Burger to the Milestone Board and look forward to her invaluable insights and contributions,” said Milestone President and CEO Gabriel Rio .
  • Dr. Burger also remains committed to the National Renewable Energy Laboratory, Activate, and is the President of the Board of Directors of the Houston Symphony.

Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in January

Retrieved on: 
Friday, February 23, 2024

The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital.

Key Points: 
  • The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital.
  • A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you.
  • A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."
  • The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes.

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.
  • We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.
  • Validating the company’s Bicycle® Radio Conjugates (BRC™) pipeline and partner for success, with updates expected from its wholly owned BRC program by mid-2024.
  • Advancing the company’s Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) immune-oncology pipeline through innovative partnerships.

Evergreen Nephrology Names New Executive Leadership

Retrieved on: 
Thursday, February 29, 2024

NASHVILLE, Tenn., Feb. 29, 2024 /PRNewswire/ -- Today, Evergreen Nephrology announced the appointment of two key executives to its leadership team, Chief Financial Officer (CFO) Philip Cooksey and Chief Medical Officer (CMO), Dr. Tim Pflederer.

Key Points: 
  • NASHVILLE, Tenn., Feb. 29, 2024 /PRNewswire/ -- Today, Evergreen Nephrology announced the appointment of two key executives to its leadership team, Chief Financial Officer (CFO) Philip Cooksey and Chief Medical Officer (CMO), Dr. Tim Pflederer.
  • Evergreen Nephrology announces appointment of executives, Philip Cooksey, CFO and Dr. Tim Pflederer, CMO.
  • Evergreen also welcomes Dr. Tim Pflederer, MD, who will begin his role as CMO on April 1.
  • These efforts can significantly improve the quality of life for patients living among the 37 million adults with kidney disease in the U.S.
    "In partnership with nephrology practices across the country, Evergreen works to delay disease progression, decrease unnecessary hospitalizations, shift care to the home, and increase transplants for CKD patients," says, Adam Boehler, Executive Chairman of Evergreen Nephrology.

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

Retrieved on: 
Friday, February 16, 2024

SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .

Key Points: 
  • SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • Pursuant and subject to the terms of the Merger Agreement, a wholly owned subsidiary of XOMA will commence a tender offer (the "Offer") by March 4, 2024 to acquire all outstanding shares of Kinnate common stock.
  • Leerink Partners is acting as lead financial advisor and Wilson Sonsini Goodrich & Rosati is acting as legal counsel to Kinnate.
  • Lazard is also acting as a financial advisor to Kinnate.

Smart Immune appoints key new members to its Board of Directors

Retrieved on: 
Friday, February 16, 2024

Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.

Key Points: 
  • Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.
  • Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are delighted and proud to welcome such distinguished experts to the Board, led by Markus Goebel as our new Chairman.
  • We are grateful to our outgoing Chairman for his 5-year commitment and support to Smart Immune.”
    Markus Goebel, CEO and Founder of M&G Advisors and Chairman of Smart Immune’s Board of Directors, said: “I am thrilled to join and lead the Board of Smart Immune.
  • He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and now an Observer on the Board of Directors at Smart Immune.

Logan Capital Management Expands Leadership with Head of Institutional Sales

Retrieved on: 
Tuesday, February 13, 2024

Logan Capital Management, Inc. (“Logan Capital”), a registered investment advisor with a series of separately managed accounts in equity and fixed-income strategies, is pleased to announce the addition of Elizabeth Fugler as Managing Director, Institutional Sales, and Client Service.

Key Points: 
  • Logan Capital Management, Inc. (“Logan Capital”), a registered investment advisor with a series of separately managed accounts in equity and fixed-income strategies, is pleased to announce the addition of Elizabeth Fugler as Managing Director, Institutional Sales, and Client Service.
  • Fugler joins Logan with over 20 years of experience leading business development in the asset management space.
  • “Elizabeth brings a wealth of knowledge to her new role, overseeing all aspects of business development and communications with consultants and institutional investors,” shared Dana Stewardson, Founding Principal of Logan Capital.
  • Prior to her role at Logan Capital, Fugler was based in New York, working for several top-tier investment firms, including Lazard Asset Management and Brown Brothers Harriman, among others.

Veteran Technology Investment Bankers Launch Arcadia Capital to Provide Mergers and Acquisitions, Financing and Strategic Advisory Services to Global Ecosystem of Emerging and Established Technology and Software Companies / Investors

Retrieved on: 
Tuesday, February 13, 2024

Accomplished technology investment bankers Mike Parker and Tristan Snyder are announcing the launch of their new firm Arcadia Capital to offer strategic advisory services to emerging and established technology and software companies / investors.

Key Points: 
  • Accomplished technology investment bankers Mike Parker and Tristan Snyder are announcing the launch of their new firm Arcadia Capital to offer strategic advisory services to emerging and established technology and software companies / investors.
  • Arcadia Capital’s suite of services include advising clients on strategic M&A, recapitalization and growth capital raises.
  • The co-founders are leveraging a combined ~40 years of experience working with premiere technology and software businesses on transformational capital markets transactions.
  • Co-CEO and Founder Mike Parker commented, “We are delighted to officially announce the launch of Arcadia Capital.